id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2015-D-1211-0368,FDA,FDA-2015-D-1211,Reference 7 Van de perre p re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry,Supporting & Related Material,Background Material,2023-05-12T04:00:00Z,2023,5,,,2023-05-12T20:07:33Z,,0,0,09000064859fc420
FDA-2015-D-1211-0397,FDA,FDA-2015-D-1211,Reference 36_FAIR_Conclusions from the For the Assessment of Individualized Risk (FAIR) group re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry,Supporting & Related Material,Background Material,2023-05-12T04:00:00Z,2023,5,,,2023-05-12T20:07:55Z,,0,0,09000064859fd93c
FDA-2015-D-1211-0402,FDA,FDA-2015-D-1211,Reference 41_Blood safety implications of donors using HIV preexposure prophylaxis re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry,Supporting & Related Material,Background Material,2023-05-12T04:00:00Z,2023,5,,,2023-05-12T20:07:59Z,,0,0,09000064859fd941
FDA-2015-D-1211-0394,FDA,FDA-2015-D-1211,Reference 33- O Brien - Donor screening question alternatives to men who have sex with men time deferral  Potential (1) re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry,Supporting & Related Material,Background Material,2023-05-12T04:00:00Z,2023,5,,,2023-05-12T20:07:52Z,,0,0,09000064859fd865
FDA-2015-D-1211-0403,FDA,FDA-2015-D-1211,Reference 42_AABB_Updated Recommendations on Donor Deferral for Use of Antiretroviral Medications for HIV Prevention and Treatment re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry,Supporting & Related Material,Background Material,2023-05-12T04:00:00Z,2023,5,,,2023-05-12T20:08:00Z,,0,0,09000064859fd942
FDA-2015-D-1211-0362,FDA,FDA-2015-D-1211,Reference 1 REV. Epstein_et_al-2013-Transfusion re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry,Supporting & Related Material,Background Material,2023-05-12T04:00:00Z,2023,5,,,2023-05-12T20:07:29Z,,0,0,09000064859fbfcf
FDA-2015-D-1211-0370,FDA,FDA-2015-D-1211,Reference 9 HIV and the blood supply re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry,Supporting & Related Material,Background Material,2023-05-12T04:00:00Z,2023,5,,,2023-05-12T20:07:35Z,,0,0,09000064859fc422
FDA-2015-D-1211-0390,FDA,FDA-2015-D-1211,Reference 29 REV. Custer - Transfusion-transmissible infection re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry,Supporting & Related Material,Background Material,2023-05-12T04:00:00Z,2023,5,,,2023-05-12T20:07:50Z,,0,0,09000064859fd861
FDA-2015-D-1211-0360,FDA,FDA-2015-D-1211,Recommendations for Evaluating Donor Eligibility Using Individual Risk- Based Questions To Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Guidance for Industry; Availability,Notice,Notice of Availability,2023-05-12T04:00:00Z,2023,5,2023-05-12T04:00:00Z,,2023-05-12T12:59:32Z,2023-10252,0,0,09000064859fa444
FDA-2015-D-1211-0387,FDA,FDA-2015-D-1211,Reference 26 Offergeld2014 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry,Supporting & Related Material,Background Material,2023-05-12T04:00:00Z,2023,5,,,2023-05-12T20:07:48Z,,0,0,09000064859fd85e
FDA-2015-D-1211-0363,FDA,FDA-2015-D-1211,Reference 2 Stramer_et_al-2013-Transfusion re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry,Supporting & Related Material,Background Material,2023-05-12T04:00:00Z,2023,5,,,2023-05-12T20:07:30Z,,0,0,09000064859fbfd0
FDA-2015-D-1211-0371,FDA,FDA-2015-D-1211,Reference 10 Current Trends Prevention of Acquired Immune Deficiency Syndrome (AIDS)_ Report of Inter-Agency Recommendations re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry,Supporting & Related Material,Background Material,2023-05-12T04:00:00Z,2023,5,,,2023-05-12T20:07:35Z,,0,0,09000064859fc423
FDA-2015-D-1211-0374,FDA,FDA-2015-D-1211,Reference 13 Donor-Testing-and-Risk-2012 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry,Supporting & Related Material,Background Material,2023-05-12T04:00:00Z,2023,5,,,2023-05-12T20:07:38Z,,0,0,09000064859fd845
FDA-2015-D-1211-0386,FDA,FDA-2015-D-1211,Reference 25 REV. Custer - Blood DROPS re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry,Supporting & Related Material,Background Material,2023-05-12T04:00:00Z,2023,5,,,2023-05-12T20:07:47Z,,0,0,09000064859fd85b
FDA-2015-D-1211-0399,FDA,FDA-2015-D-1211,Reference 38_NHS Blood and Transplant_Our Improved Donations Safety Check re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry,Supporting & Related Material,Background Material,2023-05-12T04:00:00Z,2023,5,,,2023-05-12T20:07:56Z,,0,0,09000064859fd93e
FDA-2015-D-1211-0405,FDA,FDA-2015-D-1211,Reference 44_New Ref 44_HIV incidence in US first-time blood donors during 12-month and 3-month MSM deferral policy periods re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry,Supporting & Related Material,Background Material,2023-05-12T04:00:00Z,2023,5,,,2023-05-12T20:08:01Z,,0,0,09000064859fd944
FDA-2015-D-1211-0385,FDA,FDA-2015-D-1211,Reference 24 REV. Custer2014 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry,Supporting & Related Material,Background Material,2023-05-12T04:00:00Z,2023,5,,,2023-05-12T20:07:46Z,,0,0,09000064859fd85a
FDA-2015-D-1211-0395,FDA,FDA-2015-D-1211,Reference 34 Goldman.MSM Policy changes in Canada.Transfusion.2022 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry,Supporting & Related Material,Background Material,2023-05-12T04:00:00Z,2023,5,,,2023-05-12T20:07:53Z,,0,0,09000064859fd866
FDA-2015-D-1211-0400,FDA,FDA-2015-D-1211,Reference 39_FDA_Important Information for Potential Donors of Blood and Blood Products re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry,Supporting & Related Material,Background Material,2023-05-12T04:00:00Z,2023,5,,,2023-05-12T20:07:56Z,,0,0,09000064859fd93f
FDA-2015-D-1211-0404,FDA,FDA-2015-D-1211,Reference 43 New Reference 43_HIV antiretroviral therapy and prevention use in US blood re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry,Supporting & Related Material,Background Material,2023-05-12T04:00:00Z,2023,5,,,2023-05-12T20:08:00Z,,0,0,09000064859fd943
FDA-2015-D-1211-0379,FDA,FDA-2015-D-1211,Reference 18_FDA Blood Products Advisory Committee Meeting_September 14-15 2000 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry,Supporting & Related Material,Background Material,2023-05-12T04:00:00Z,2023,5,,,2023-05-12T20:07:41Z,,0,0,09000064859fd84a
FDA-2015-D-1211-0384,FDA,FDA-2015-D-1211,Reference 23 REV. ACBTSA re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry,Supporting & Related Material,Background Material,2023-05-12T04:00:00Z,2023,5,,,2023-05-12T20:07:46Z,,0,0,09000064859fd859
FDA-2015-D-1211-0392,FDA,FDA-2015-D-1211,Refernce 31_HIV Risk Behavior Profiles Among Men Who Have Sex with Men Interested in Donating Blood_ADVANCE Study re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry,Supporting & Related Material,Background Material,2023-05-12T04:00:00Z,2023,5,,,2023-05-12T20:07:51Z,,0,0,09000064859fd863
FDA-2015-D-1211-0401,FDA,FDA-2015-D-1211,Reference 40_Initiation of anti-retroviral therapy during acute HIV-1 infection leads to a high rate of nonreactive HIV serology re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry,Supporting & Related Material,Background Material,2023-05-12T04:00:00Z,2023,5,,,2023-05-12T20:07:57Z,,0,0,09000064859fd940
FDA-2015-D-1211-0367,FDA,FDA-2015-D-1211,Reference 6 Pubhealthrep00106-0104 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry,Supporting & Related Material,Background Material,2023-05-12T04:00:00Z,2023,5,,,2023-05-12T20:07:33Z,,0,0,09000064859fbfd4
FDA-2015-D-1211-0372,FDA,FDA-2015-D-1211,Reference 11 Transfusion-associated_infections re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry,Supporting & Related Material,Background Material,2023-05-12T04:00:00Z,2023,5,,,2023-05-12T20:07:36Z,,0,0,09000064859fd727
FDA-2015-D-1211-0380,FDA,FDA-2015-D-1211,Reference 19 FDA Workshop on Behavior-Based Donor Deferral in the NAT Era 2006 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry,Supporting & Related Material,Background Material,2023-05-12T04:00:00Z,2023,5,,,2023-05-12T20:07:42Z,,0,0,09000064859fd84b
FDA-2015-D-1211-0383,FDA,FDA-2015-D-1211,Reference 22_FDA workshop on Quarantine Release Errors in Blood Establishments_September 2011 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry,Supporting & Related Material,Background Material,2023-05-12T04:00:00Z,2023,5,,,2023-05-12T20:07:45Z,,0,0,09000064859fd858
FDA-2015-D-1211-0393,FDA,FDA-2015-D-1211,Reference 32_Caffrey_Removing MSM.Canada.CliniqueTransfusion.2022 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry,Supporting & Related Material,Background Material,2023-05-12T04:00:00Z,2023,5,,,2023-05-12T20:07:52Z,,0,0,09000064859fd864
FDA-2015-D-1211-0376,FDA,FDA-2015-D-1211,Reference 15 MMWR_Revised Public Health Service Definition of Persons Who Should Refrain from Donating Blood and Plasma -- United States re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry,Supporting & Related Material,Background Material,2023-05-12T04:00:00Z,2023,5,,,2023-05-12T20:07:39Z,,0,0,09000064859fd847
FDA-2015-D-1211-0389,FDA,FDA-2015-D-1211,Reference 28 Lucky2014 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry,Supporting & Related Material,Background Material,2023-05-12T04:00:00Z,2023,5,,,2023-05-12T20:07:49Z,,0,0,09000064859fd860
FDA-2015-D-1211-0398,FDA,FDA-2015-D-1211,Reference 37_Patel et al_Estimating per-act HIV transmission risk re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry,Supporting & Related Material,Background Material,2023-05-12T04:00:00Z,2023,5,,,2023-05-12T20:07:55Z,,0,0,09000064859fd93d
FDA-2015-D-1211-0406,FDA,FDA-2015-D-1211,Reference 45_New Ref 45_Modeling the Effect of an Individual-Risk Based Deferral Policy re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry,Supporting & Related Material,Background Material,2023-05-12T04:00:00Z,2023,5,,,2023-05-12T20:08:02Z,,0,0,09000064859fd945
FDA-2015-D-1211-0364,FDA,FDA-2015-D-1211,Reference 3 Dubin_et_al-2013-Transfusion re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry,Supporting & Related Material,Background Material,2023-05-12T04:00:00Z,2023,5,,,2023-05-12T20:07:31Z,,0,0,09000064859fbfd1
FDA-2015-D-1211-0365,FDA,FDA-2015-D-1211,Reference 4 Epidemiologic Notes and Reports Pneumocystis carinii Pneumonia among Persons with Hemophilia A re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry,Supporting & Related Material,Background Material,2023-05-12T04:00:00Z,2023,5,,,2023-05-12T20:07:31Z,,0,0,09000064859fbfd2
FDA-2015-D-1211-0366,FDA,FDA-2015-D-1211,Reference 5 Epidemiologic Notes and Reports Possible Transfusion-Associated Acquired Immune Deficiency Syndrome (AIDS) -- California re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry,Supporting & Related Material,Background Material,2023-05-12T04:00:00Z,2023,5,,,2023-05-12T20:07:32Z,,0,0,09000064859fbfd3
FDA-2015-D-1211-0375,FDA,FDA-2015-D-1211,Reference 14 Klamroth2014 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry,Supporting & Related Material,Background Material,2023-05-12T04:00:00Z,2023,5,,,2023-05-12T20:07:38Z,,0,0,09000064859fd846
FDA-2015-D-1211-0373,FDA,FDA-2015-D-1211,Reference 12 Ward et al_JAMA_256_3_028 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry,Supporting & Related Material,Background Material,2023-05-12T04:00:00Z,2023,5,,,2023-05-12T20:07:37Z,,0,0,09000064859fd844
FDA-2015-D-1211-0361,FDA,FDA-2015-D-1211,Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry,Other,Guidance,2023-05-12T04:00:00Z,2023,5,2023-05-12T04:00:00Z,,2024-11-11T21:24:16Z,,1,0,09000064859fa827
FDA-2015-D-1211-0369,FDA,FDA-2015-D-1211,Reference 8 FDA Memorandum Recommendations to decrease the Risk of Tramitting AIDS fro Blood donors re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry,Supporting & Related Material,Background Material,2023-05-12T04:00:00Z,2023,5,,,2023-05-12T20:07:34Z,,0,0,09000064859fc421
FDA-2015-D-1211-0377,FDA,FDA-2015-D-1211,Reference 16_FDA Blood Products Advisory Committee Meeting_December 11 1997 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry,Supporting & Related Material,Background Material,2023-05-12T04:00:00Z,2023,5,,,2023-05-12T20:07:40Z,,0,0,09000064859fd848
FDA-2015-D-1211-0396,FDA,FDA-2015-D-1211,Reference 35_Advisory Committee on the Safety of Blood Tissues and Organs (SaBTO)_Donor Selection Criteria Report re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry,Supporting & Related Material,Background Material,2023-05-12T04:00:00Z,2023,5,,,2023-05-12T20:07:54Z,,0,0,09000064859fd867
FDA-2015-D-1211-0378,FDA,FDA-2015-D-1211,Reference 17_FDA Workshop on Donor Suitability 1998 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry,Supporting & Related Material,Background Material,2023-05-12T04:00:00Z,2023,5,,,2023-05-12T20:07:40Z,,0,0,09000064859fd849
FDA-2015-D-1211-0382,FDA,FDA-2015-D-1211,Reference 21 Quarantine-release-errors-white-paper re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry,Supporting & Related Material,Background Material,2023-05-12T04:00:00Z,2023,5,,,2023-05-12T20:07:44Z,,0,0,09000064859fd84d
FDA-2015-D-1211-0391,FDA,FDA-2015-D-1211,Reference 30_ADVANCE Study re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry,Supporting & Related Material,Background Material,2023-05-12T04:00:00Z,2023,5,,,2023-05-12T20:07:50Z,,0,0,09000064859fd862
FDA-2015-D-1211-0381,FDA,FDA-2015-D-1211,Reference 20 HHS Advisory Committee for blood safety and availability mtg 2010 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry,Supporting & Related Material,Background Material,2023-05-12T04:00:00Z,2023,5,,,2023-05-12T20:07:43Z,,0,0,09000064859fd84c
FDA-2015-D-1211-0388,FDA,FDA-2015-D-1211,Reference 27 Seed2010 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry,Supporting & Related Material,Background Material,2023-05-12T04:00:00Z,2023,5,,,2023-05-12T20:07:48Z,,0,0,09000064859fd85f
FDA-2015-D-1211-0274,FDA,FDA-2015-D-1211,Guidance Documents Related to Coronavirus Disease 2019 (COVID–19),Notice,General Notice,2023-03-13T04:00:00Z,2023,3,2023-03-13T04:00:00Z,,2023-03-13T14:09:01Z,2023-05094,0,0,090000648579b2d7
FDA-2015-D-1211-0151,FDA,FDA-2015-D-1211,Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions To Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Draft Guidance for Industry; Availability,Notice,Notice of Availability,2023-01-30T05:00:00Z,2023,1,2023-01-30T05:00:00Z,,2023-02-28T14:29:29Z,2023-01796,0,0,0900006485618fef
FDA-2015-D-1211-0155,FDA,FDA-2015-D-1211,Reference 17_FDA Workshop on Donor Suitability 1998,Supporting & Related Material,Background Material,2023-01-30T05:00:00Z,2023,1,,,2023-01-30T14:18:43Z,,0,0,0900006485618a78
FDA-2015-D-1211-0156,FDA,FDA-2015-D-1211,Reference 18_FDA Blood Products Advisory Committee Meeting_September 14-15 2000,Supporting & Related Material,Background Material,2023-01-30T05:00:00Z,2023,1,,,2023-01-30T14:19:40Z,,0,0,0900006485618a79
FDA-2015-D-1211-0157,FDA,FDA-2015-D-1211,Reference 19 FDA Workshop on Behavior-Based Donor Deferral in the NAT Era 2006,Supporting & Related Material,Background Material,2023-01-30T05:00:00Z,2023,1,,,2023-01-30T14:20:46Z,,0,0,0900006485618a6b
FDA-2015-D-1211-0158,FDA,FDA-2015-D-1211,Reference 22_FDA workshop on Quarantine Release Errors in Blood Establishments_September 2011,Supporting & Related Material,Background Material,2023-01-30T05:00:00Z,2023,1,,,2023-01-30T14:21:52Z,,0,0,0900006485618a6c
FDA-2015-D-1211-0152,FDA,FDA-2015-D-1211,Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions To Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Draft Guidance for Industry; Availability,Other,Guidance,2023-01-30T05:00:00Z,2023,1,2023-01-30T05:00:00Z,2023-04-01T03:59:59Z,2025-02-05T02:00:53Z,,1,0,0900006485618a68
FDA-2015-D-1211-0159,FDA,FDA-2015-D-1211,New Reference 30_ADVANCE Study,Supporting & Related Material,Background Material,2023-01-30T05:00:00Z,2023,1,,,2023-01-30T14:22:43Z,,0,0,0900006485618a6d
FDA-2015-D-1211-0160,FDA,FDA-2015-D-1211,New Ref 32- O Brien - Donor screening question alternatives to men who have sex with men time deferral  Potential (1),Supporting & Related Material,Background Material,2023-01-30T05:00:00Z,2023,1,,,2023-01-30T14:24:06Z,,0,0,0900006485618a6e
FDA-2015-D-1211-0154,FDA,FDA-2015-D-1211,Reference 16_FDA Blood Products Advisory Committee Meeting_December 11 1997,Supporting & Related Material,Background Material,2023-01-30T05:00:00Z,2023,1,,,2023-01-30T14:17:37Z,,0,0,0900006485618a77
FDA-2015-D-1211-0153,FDA,FDA-2015-D-1211,New Ref 15 MMWR_Revised Public Health Service Definition of Persons Who Should Refrain from Donating Blood and Plasma -- United States,Supporting & Related Material,Background Material,2023-01-30T05:00:00Z,2023,1,,,2023-01-30T14:17:49Z,,0,0,0900006485618a6a
FDA-2015-D-1211-0161,FDA,FDA-2015-D-1211,New Ref 37_NHS Blood and Transplant_Our Improved Donations Safety Check,Supporting & Related Material,Background Material,2023-01-30T05:00:00Z,2023,1,,,2023-01-30T14:24:58Z,,0,0,0900006485618a7c